Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Acrocephalosyndactylia × E-3810 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2 Small Cell Lung Carcinoma 1 Neoplasms 1 Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Acrocephalosyndactylia 1

Interventions

pemigatinib 5 Rogaratinib 2 pembrolizumab 1 lenvatinib 1 infigratinib 1 erdafitinib 1 brivanib 1 Rabeprazole 1 Irinotecan 1 INCB 54828-101 1 Gemcitabine 1 E-3810 1 Drug Combinations 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02747797 2018-08-02

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

University of California, San Diego

Phase 2 Withdrawn

Acrocephalosyndactylia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡